Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects (PO206)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00979251
Recruitment Status : Completed
First Posted : September 17, 2009
Last Update Posted : April 14, 2014
Information provided by (Responsible Party):
Adamas Pharmaceuticals, Inc.

Brief Summary:
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.

Condition or disease Intervention/treatment Phase
Influenza Drug: Oseltamivir Phosphate Drug: ADS-8902 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects
Study Start Date : September 2009
Actual Primary Completion Date : May 2010
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: ADS-8902
Amantadine and Ribavirin administered with Oseltamivir phosphate
Drug: ADS-8902
Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
Other Names:
  • Amantadine Hydrochloride
  • Rebetol®
  • Tamiflu®

Active Comparator: Comparator
Oseltamivir Phosphate
Drug: Oseltamivir Phosphate
Oseltamivir Phosphate, q8h
Other Name: Tamiflu

Primary Outcome Measures :
  1. Time to clearing of viral shedding [ Time Frame: Baseline, Days 2, 4, 6, 8, 10, 15 and 20 ]

Secondary Outcome Measures :
  1. Time to alleviation of influenza clinical symptoms [ Time Frame: Baseline, Days 2, 4, 6, 8, 10, 15, 20, 38 ]
  2. Proportion of subjects who enter the study with mild to moderate influenza and progress to severe influenza [ Time Frame: Baseline, Days 2, 4, 6, 8, 10, 15, 20, 38 ]
  3. Proportion of subjects with a treatment-sensitive influenza A strain at baseline who develop a resistant strain during treatment [ Time Frame: Baseline, Days 2, 4, 6, 8, 10, 15, 20 ]
  4. Safety and tolerability (adverse events (AEs), AEs resulting in treatment discontinuation, and Serious AEs) [ Time Frame: Through day 210 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed influenza A by rapid antigen testing
  • Immunocompromised as defined by recent solid organ or hematopoietic transplant, chronic graft vs. host disease, taking at least 2 immunosuppressants, undergoing chemotherapy, taking high dose chemotherapeutics, HIV positive
  • Clinical diagnosis of influenza
  • Onset of illness within 5 days
  • Male and female subjects agree to contraception through 24 weeks after last dose

Exclusion Criteria:

  • Received more than 1 dose of antiviral agents
  • Critically ill
  • Creatinine clearance less than 80 mg/mL
  • Females who are pregnant and males whose female partners are pregnant
  • Received live attenuated virus vaccine within 3 weeks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00979251

Layout table for location information
United States, California
Adamas Investigational Site
San Francisco, California, United States, 94114
Adamas Investigational Site
San Francisco, California, United States, 94115
Adamas Investigational Site
San Francisco, California, United States
United States, Florida
Adamas Investigational Site
Hollywood, Florida, United States
Adamas Investigational Site
Miramar, Florida, United States
Adamas Investigational Site
Pinellas Park, Florida, United States
United States, Hawaii
Adamas Investigational Site
Honolulu, Hawaii, United States
United States, Kentucky
Adamas Investigational Site
Owensboro, Kentucky, United States
United States, Louisiana
Adamas Investigational Site
New Orleans, Louisiana, United States
United States, Nevada
Adamas Investigational Site
Las Vegas, Nevada, United States
United States, New York
Adamas Investigational Site
New York, New York, United States
United States, South Dakota
Adamas Investigational Site
Rapid City, South Dakota, United States, 57702
United States, Tennessee
Adamas Investigational Site
Memphis, Tennessee, United States, 38105
United States, Texas
Adamas Investigational Site
Amarillo, Texas, United States
United States, Washington
Adamas Investigational Site
Seattle, Washington, United States
Adamas Investigational Site
Tacoma, Washington, United States
Australia, New South Wales
Adamas Investigational Site
Darlinghurst, New South Wales, Australia, NSW 2010
Adamas Investigational Site
Herston, New South Wales, Australia, QLD 4029
Adamas Investigational Site
Sydney, New South Wales, Australia, QLD 4029
Australia, Victoria
Adamas Investigative Site
Parkville, Victoria, Australia, 3050
Adamas Investigational Site
Melbourne, Australia
Canada, Alberta
Adamas Investigational Site
Edmonton, Alberta, Canada
Canada, Ontario
Adamas Investigational Site
Toronto, Ontario, Canada
Adamas Investigational Site
Leiden, Netherlands
Adamas Investigational Site
Singapore, Singapore
Sponsors and Collaborators
Adamas Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Adamas Pharmaceuticals, Inc. Identifier: NCT00979251    
Other Study ID Numbers: ADS-TCAD-PO206
First Posted: September 17, 2009    Key Record Dates
Last Update Posted: April 14, 2014
Last Verified: March 2014
Keywords provided by Adamas Pharmaceuticals, Inc.:
History of transplant
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Respiratory Tract Infections
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents